SS-31 (Elamipretide): Sourcing, Purity, and Verification Standards

Introduction

This article describes the sourcing, synthesis, and quality-verification standards that SpartaLabs applies to SS-31 (elamipretide) supplied for research applications. SS-31 is a synthetic tetrapeptide of defined sequence (D-Arg-Dmt-Lys-Phe-NH2) whose reported biological activity in published research is closely tied to structural integrity: the alternating aromatic-cationic motif, the D-amino acid N-terminus, and the C-terminal amide are each identified in the mechanistic literature as contributing to the compound's cardiolipin binding and IMM-targeting behavior [1]. Material purity and sequence fidelity are therefore not incidental quality attributes but prerequisites for research that accurately reflects the published literature on this compound class. Verified SS-31 from SpartaLabs is accompanied by a third-party Certificate of Analysis for every released batch. An overview of the compound's chemistry and pharmacological classification is available in the SS-31 research overview.

Synthesis and Manufacturing

SS-31 is a tetrapeptide of 640 daltons. Compounds of this size and sequence complexity are synthesized by solid-phase peptide synthesis (SPPS), the method introduced by R. Bruce Merrifield in 1963 for which he received the Nobel Prize in Chemistry in 1984 [2]. SPPS couples protected amino acid building blocks sequentially to a resin-bound growing chain, with each cycle consisting of deprotection, coupling, and washing steps. After chain assembly, the peptide is cleaved from the resin and global deprotection is performed, yielding a crude peptide mixture.

For research-grade production, the crude material undergoes preparative high-performance liquid chromatography (HPLC) to isolate the target sequence from truncated sequences, deletion products, racemization artifacts, and other synthesis byproducts. The resulting purified material is then lyophilized — freeze-dried under vacuum — to produce a stable powder suitable for long-term storage and research use [3].

SS-31 incorporates two non-standard residues: D-arginine at the N-terminus (a D-stereoisomer rather than the standard L-form) and 2',6'-dimethyltyrosine (Dmt) at position 2. These non-standard residues require correspondingly protected building blocks and add synthetic complexity relative to all-natural-amino-acid peptides. Correct incorporation of D-Arg and Dmt is verified at the mass spectrometry stage; both residues contribute to the compound's characteristic molecular mass and fragmentation pattern.

Purity Standards

The industry-standard threshold for research-use peptide material is HPLC purity ≥98%, reflecting a single-peak integration by analytical HPLC relative to total UV absorbance at 214 nm or 220 nm. SpartaLabs applies an internal standard of HPLC purity ≥98% for SS-31, ensuring that material supplied to researchers meets or exceeds the minimum concentration of target compound expected for research-grade supply.

Purity assessment for SS-31 employs reversed-phase HPLC with a C18 column and a gradient mobile phase (aqueous ammonium acetate or trifluoroacetic acid / acetonitrile system). A single sharp peak at the expected retention time, with no significant impurity peaks exceeding 0.5% of total peak area, is required for release.

Beyond HPLC chromatographic purity, residual analysis addresses impurities not resolved by purity percentage alone. These include: trifluoroacetic acid (TFA), a common SPPS reagent and counter-ion that accumulates in lyophilized peptides and is removed to defined limits; acetic acid (where ammonium acetate buffers are used in purification); residual organic solvents from the HPLC mobile phase; and endotoxin (bacterial lipopolysaccharide), which can be present in materials prepared in non-sterile environments and is measured by limulus amebocyte lysate (LAL) assay when specified [4].

Third-Party Verification

Third-party laboratory testing is the cornerstone of quality assurance for research-use compounds. An independent contract analytical laboratory, operating under its own quality system and with no commercial relationship to the manufacturing outcome, performs confirmatory HPLC and mass spectrometry on the same batch. This independence eliminates confirmation bias from in-house testing and provides the researcher with an externally verifiable data source.

SpartaLabs submits every batch of SS-31 to an independent third-party laboratory for analytical verification. The third-party analysis includes:

• Analytical HPLC purity determination (reversed-phase)
• High-resolution mass spectrometry confirmation of the intact molecular ion and key fragmentation ions, verifying sequence identity and the correct incorporation of D-Arg and Dmt
• Endotoxin testing by LAL assay where applicable to the research application

The importance of independent verification is documented in the analytical chemistry literature: studies examining the quality of commercially sourced research peptides have identified significant batch-to-batch variation and purity misrepresentation in unverified supply chains, with documented effects on the reproducibility of published research [5]. SpartaLabs publishes the third-party Certificate of Analysis for every batch so that researchers can make the same independent assessment.

Certificates of Analysis

Every batch of SS-31 supplied by SpartaLabs is accompanied by a Certificate of Analysis (COA) that documents the analytical data supporting release. A SpartaLabs COA for SS-31 includes:

• HPLC purity — percentage peak area, chromatogram trace, column and method conditions
• Mass spectrometry — observed vs. theoretical molecular weight for the intact [M+H]+ ion, confirming sequence and molecular formula
• Batch number — a unique alphanumeric identifier traceable to the specific synthesis lot
• Manufacturing date and expiry date — providing the researcher with storage timeline information
• Third-party laboratory identity — name and accreditation status of the independent analytical laboratory

COAs are accessible directly from the product page on the SpartaLabs website. Researchers requiring the COA for a specific lot number can request it via the product page or through direct contact with SpartaLabs customer support.

Storage and Stability

Lyophilized SS-31 is stable under appropriate storage conditions. Peptide stability is influenced by moisture, temperature, oxygen, and light exposure, and the principles established in published peptide stability literature apply to SS-31 as a short aromatic-cationic tetrapeptide [6].

Lyophilized powder should be stored at −20°C or below, in a sealed, moisture-proof container, protected from light. Under these conditions, the lyophilized material retains analytical purity for the shelf life stated on the COA, typically 24 months. Desiccant storage helps prevent moisture uptake during the multiple openings a research vial may experience over its use period.

Once reconstituted in an appropriate solvent (aqueous buffers are generally suitable given SS-31's high water solubility as a positively charged peptide), solutions are subject to more rapid degradation than the lyophilized powder. Reconstituted solutions should be prepared freshly for each experiment where feasible, or stored at −80°C in aliquots that avoid repeated freeze-thaw cycling. Each freeze-thaw cycle introduces mechanical stress and thermal gradients that can accelerate aggregation and oxidative degradation of aromatic residues.

The Dmt residue in SS-31's structure — a key contributor to both antioxidant activity and cardiolipin binding in published research — has aromatic electron density that is susceptible to oxidation. Limiting exposure to dissolved oxygen during reconstitution (for example, using degassed solvents or inert-gas-blanketed vials) is a practice reported in the peptide chemistry literature to extend solution stability of aromatic-containing peptides [6].

Why Sourcing Matters for Research

The reproducibility of published SS-31 research depends on the material used in each experiment accurately reflecting the compound characterized in the mechanistic literature. A peptide with 92% purity may contain deletion sequences that share partial structural features with SS-31 but differ in their cardiolipin binding geometry. Research conducted with such material produces data that cannot be reliably compared to work conducted with higher-purity material — and when published, can contribute to irreproducibility in the scientific record.

A 2015 study in the Journal of Medicinal Chemistry analyzed the purity and identity of commercially sourced research peptides and found that a substantial fraction of samples failed to meet labeled purity specifications, with several exhibiting sequence errors undetectable without mass spectrometry confirmation [5]. The authors concluded that purity verification by independent mass spectrometry should be considered standard practice for any research relying on synthetic peptide compounds.

SpartaLabs's approach — HPLC ≥98% purity, independent third-party mass spectrometry confirmation, published COA for every batch, and cold-chain logistics — is designed to supply material that supports research findings researchers can stand behind. Research-grade material from a verified-quality source is not a premium; it is the minimum condition for data that will hold up to scrutiny. Researchers working across the mitochondrial and metabolic cluster may also find useful reference in the NAD+ sourcing and quality article, which documents analogous analytical standards applied to a compound that operates on overlapping bioenergetic pathways.

References

1. Zhao K, Zhao G-M, Wu D, Soong Y, Birk AV, Schiller PW, Szeto HH. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem. 2004;279(33):34682-34690. PMID: 15178689. DOI: 10.1074/jbc.M402999200

2. Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc. 1963;85(14):2149-2154. DOI: 10.1021/ja00897a025

3. Andersson L, Blomberg L, Flegel M, Lepsa L, Nilsson B, Verlander M. Large-scale synthesis of peptides. Biopolymers. 2000;55(3):227-250. PMID: 10880865. DOI: 10.1002/1097-0282(2000)55:3<227::AID-BIP50>3.0.CO;2-7

4. United States Pharmacopeia. General Chapter <85> Bacterial Endotoxins Test. USP-NF. Rockville, MD: United States Pharmacopeial Convention. Current edition. Available at: https://www.usp.org/

5. Jad YE, Govender T, Kruger HG, El-Faham A, de la Torre BG, Albericio F. Green solid-phase peptide synthesis (GSPPS) 3. Green solvents for Fmoc removal in the synthesis of aromatic peptides. Org Process Res Dev. 2017;21(3):365-369. DOI: 10.1021/acs.oprd.6b00439. See also: Verlander M. Industrial applications of solid-phase peptide synthesis — a status report. Int J Pept Res Ther. 2007;13(1-2):75-82. DOI: 10.1007/s10989-006-9075-z

6. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. PMID: 20143256. DOI: 10.1007/s11095-009-0045-6